| human | Q5 |
| P496 | ORCID iD | 0000-0003-4627-1714 |
| P1153 | Scopus author ID | 7005262686 |
| P734 | family name | Antin | Q24800469 |
| Antin | Q24800469 | ||
| Antin | Q24800469 | ||
| P735 | given name | Joseph | Q471788 |
| Joseph | Q471788 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q44563918 | A 41-year-old woman with chronic myelogenous leukemia |
| Q36157163 | A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial |
| Q52725666 | A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. |
| Q34308142 | A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome |
| Q36141944 | A disease risk index for patients undergoing allogeneic stem cell transplantation |
| Q78409959 | A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation |
| Q84580141 | A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast |
| Q41273685 | A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation |
| Q35737769 | A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease |
| Q90731240 | A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation |
| Q36402045 | A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. |
| Q35177453 | A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality |
| Q43887198 | A survey of diagnosis, management, and grading of chronic GVHD. |
| Q89778012 | ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint |
| Q43458651 | Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome |
| Q36527645 | Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation |
| Q28299225 | Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation |
| Q64122325 | Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia |
| Q92500578 | Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma |
| Q43808864 | Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation |
| Q36404698 | Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia |
| Q34608688 | Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials |
| Q36797694 | Allogeneic stem cell transplantation for aplastic anemia |
| Q40765997 | Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission |
| Q36624952 | Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome |
| Q33756719 | Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival |
| Q37162874 | Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease |
| Q33815631 | Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. |
| Q34226161 | American journal of cancer research: editorial board (2011) |
| Q38824856 | An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. |
| Q33798102 | An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition |
| Q36303244 | An overview of hematopoietic stem cell transplantation |
| Q33847973 | Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. |
| Q35533586 | Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. |
| Q47402442 | Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease |
| Q34312702 | Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors |
| Q24539030 | Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission |
| Q36321274 | Approaches to graft-vs-host disease |
| Q90441813 | Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation |
| Q53440895 | Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. |
| Q37123927 | Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells |
| Q36725446 | Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial |
| Q42231317 | BK virus disease after allogeneic stem cell transplantation: a cohort analysis. |
| Q94571349 | BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation |
| Q37354189 | Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation |
| Q37603176 | Biology and management of acute graft-versus-host disease |
| Q50079874 | Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials |
| Q81471264 | Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007 |
| Q35591760 | Blood and marrow transplant clinical trials network state of the Science Symposium 2014 |
| Q34079116 | Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors |
| Q36212400 | Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation |
| Q50078364 | Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results |
| Q89741761 | Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study |
| Q43628597 | Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia |
| Q79077287 | CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD |
| Q35177449 | Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort |
| Q53038031 | Characterization of oral involvement in acute graft-versus-host disease. |
| Q90925290 | Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
| Q35067642 | Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis |
| Q82485966 | Chronic graft-versus-host disease |
| Q36920466 | Circulating T follicular helper cells with increased function during chronic graft-versus-host disease |
| Q35574597 | Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study |
| Q36025790 | Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis |
| Q53509045 | Clinical evaluation of oral chronic graft-versus-host disease. |
| Q74410516 | Clinical practice. Long-term care after hematopoietic-cell transplantation in adults |
| Q34548829 | Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. |
| Q48076820 | Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome |
| Q40524119 | Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma |
| Q35687151 | Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation |
| Q78605163 | Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation |
| Q91179887 | Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation |
| Q34354733 | Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. |
| Q53414869 | Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. |
| Q37238884 | Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat |
| Q44253438 | Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations |
| Q94510967 | Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT |
| Q57413787 | Contribution of bone marrow–derived endothelial cells to human tumor vasculature |
| Q56658085 | Cord Colitis Syndrome in Cord-Blood Stem-Cell Transplantation |
| Q38783854 | Cord blood versus haploidentical stem cell transplantation for hematological malignancies |
| Q37276889 | Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. |
| Q100517644 | Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease |
| Q36485256 | Costs of allogeneic hematopoietic cell transplantation with high-dose regimens |
| Q33642625 | Current and future approaches for control of graft-versus-host disease |
| Q36884109 | Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study |
| Q57053213 | Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis |
| Q38913054 | Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. |
| Q89009287 | Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program |
| Q34207695 | Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial |
| Q80439335 | Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome |
| Q74794190 | Development and validation of a scale to measure symptoms of chronic graft-versus-host disease |
| Q33709766 | Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes |
| Q35981569 | Does iron overload really matter in stem cell transplantation? |
| Q35776453 | Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans |
| Q35769347 | Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival |
| Q78410601 | Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation |
| Q36119872 | Donor leukocyte infusions and graft-versus-malignancy |
| Q36602049 | Donor leukocyte infusions in myeloid malignancies: new strategies |
| Q33952705 | Donor-derived second hematologic malignancies after cord blood transplantation |
| Q48228263 | Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias |
| Q33583414 | Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease |
| Q37685590 | Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. |
| Q93021290 | Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children |
| Q34162647 | Double unrelated reduced-intensity umbilical cord blood transplantation in adults |
| Q38818973 | Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation |
| Q90776206 | Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation |
| Q36920445 | Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis |
| Q91609109 | Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant |
| Q38877341 | Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia |
| Q35197402 | Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia |
| Q44892383 | Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial |
| Q64089247 | Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease |
| Q36708930 | Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation |
| Q37076418 | Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease |
| Q38786084 | Emerging drugs for graft-versus-host disease |
| Q58415140 | Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy |
| Q58928278 | Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells |
| Q46543205 | Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation |
| Q35847663 | Evidence for ineffective erythropoiesis in severe sickle cell disease |
| Q35750957 | Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation |
| Q45009148 | Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host dis |
| Q90304053 | Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation |
| Q35038942 | Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation |
| Q88692412 | Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome |
| Q102141777 | Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
| Q36916440 | Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels |
| Q39548190 | Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma |
| Q91246229 | Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation |
| Q64089252 | Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease |
| Q36865630 | HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. |
| Q37158269 | HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia |
| Q40513646 | Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission |
| Q35976578 | Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia |
| Q46878801 | Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study |
| Q95313932 | Hematopoietic Stem Cell Transplant for Shwachman Diamond Syndrome |
| Q34479575 | Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome |
| Q34135089 | High levels of B-cell activating factor in patients with active chronic graft-versus-host disease |
| Q37391113 | High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults |
| Q37247613 | Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. |
| Q35692767 | IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults |
| Q35140097 | Ibrutinib treatment ameliorates murine chronic graft-versus-host disease |
| Q35784548 | Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation |
| Q36025309 | Immune reconstitution: the major barrier to successful stem cell transplantation |
| Q35542959 | Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia |
| Q58415027 | Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation |
| Q34577019 | Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. |
| Q37345807 | Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation |
| Q34198055 | Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia |
| Q40989464 | Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years |
| Q33816027 | Improved survival after acute graft-versus-host disease diagnosis in the modern era. |
| Q41876102 | Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning |
| Q91071045 | Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation |
| Q33781179 | Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans |
| Q36036340 | Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. |
| Q38848582 | Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation |
| Q92489808 | Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation |
| Q57053392 | Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study |
| Q30277751 | Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation |
| Q91164990 | Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease |
| Q89046045 | Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors |
| Q78410438 | Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation |
| Q37055805 | Interleukin-2 and regulatory T cells in graft-versus-host disease |
| Q57053301 | Invasive Fungal Disease after Remote Inoculation in Transplant Recipients |
| Q113869593 | Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome |
| Q37491836 | Ipilimumab for Patients with Relapse after Allogeneic Transplantation. |
| Q33905984 | Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis |
| Q42879186 | Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation |
| Q37637836 | Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. |
| Q39140025 | Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients |
| Q24635839 | Launching of American Journal of Cancer Research |
| Q42239521 | Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients |
| Q34749391 | Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy |
| Q35525729 | Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. |
| Q37377103 | Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells |
| Q36940174 | Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease |
| Q45059587 | Mammalian target of rapamycin inhibition as therapy for hematologic malignancies |
| Q47144306 | Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts |
| Q37359876 | Mental status changes after hematopoietic stem cell transplantation |
| Q34866557 | Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient |
| Q24537575 | Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation |
| Q37344320 | Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. |
| Q35934119 | Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation |
| Q46450537 | Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens |
| Q44189562 | Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome |
| Q36962653 | Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation |
| Q34649014 | Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation |
| Q34202277 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio |
| Q47603352 | Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma |
| Q35897164 | Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease |
| Q37239863 | Novel drugs for the prevention and treatment of acute GVHD. |
| Q38094336 | Ocular graft-versus-host disease: a review |
| Q47821844 | Optimistic expectations and survival after hematopoietic stem cell transplantation |
| Q34645147 | Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Ne |
| Q40086900 | Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. |
| Q37359736 | Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation |
| Q47563827 | Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma |
| Q51056679 | Outcomes and management strategies for graft failure after umbilical cord blood transplantation. |
| Q44447834 | Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies |
| Q37077955 | Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita |
| Q40354412 | PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy |
| Q33347659 | Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study |
| Q56482659 | Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease |
| Q34551192 | Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. |
| Q36755484 | Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure |
| Q50820581 | Phase I clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. |
| Q36813127 | Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease |
| Q34620695 | Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia |
| Q80502490 | Phase I trial of parathyroid hormone to facilitate stem cell mobilization |
| Q41718552 | Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma |
| Q99207677 | Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease |
| Q36395129 | Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. |
| Q38932342 | Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production |
| Q37585022 | Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. |
| Q92287861 | Positive psychological experiences in allogeneic hematopoietic stem cell transplantation |
| Q37700864 | Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease |
| Q42737854 | Prediction of veno-occlusive disease using biomarkers of endothelial injury |
| Q45042788 | Predictors of 1-year survival assessed at the time of bone marrow transplantation |
| Q79329004 | Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia |
| Q28203306 | Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation |
| Q35970489 | Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation |
| Q89607362 | Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network |
| Q42158416 | Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation |
| Q93115037 | Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report |
| Q35828727 | Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation |
| Q78410152 | Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation |
| Q35848083 | Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR |
| Q37263182 | Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation |
| Q44088518 | Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. |
| Q46376580 | Psychosocial function after hematopoietic stem cell transplantation |
| Q91323319 | Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial |
| Q58415147 | Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion |
| Q93130280 | Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells |
| Q38993099 | Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. |
| Q34707354 | Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease |
| Q92033372 | Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation |
| Q35848361 | Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease |
| Q37007254 | Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. |
| Q33838116 | Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age |
| Q46816156 | Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts |
| Q37457111 | Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. |
| Q91787997 | Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients |
| Q89510703 | Relationship Between Intestinal Bacteria and the Anticancer Effect of Hematopoietic Stem-Cell Transplantation |
| Q30702793 | Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem c |
| Q35485880 | Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease |
| Q35651735 | Risk factors for acute GVHD and survival after hematopoietic cell transplantation |
| Q74500519 | Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation |
| Q38284510 | Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival |
| Q35848933 | Rituximab for steroid-refractory chronic graft-versus-host disease |
| Q37113099 | Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial |
| Q37618997 | ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death |
| Q40386808 | Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. |
| Q36768621 | Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease |
| Q47685290 | Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q57053222 | Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation |
| Q36846282 | Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. |
| Q53170671 | Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. |
| Q34362427 | Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome |
| Q39143739 | Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation |
| Q30394925 | Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. |
| Q53313339 | Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. |
| Q37621636 | Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? |
| Q34087133 | Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse |
| Q43790464 | Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation |
| Q33366979 | Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation |
| Q37780663 | Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update |
| Q37001941 | Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation |
| Q37247581 | Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation |
| Q44107506 | Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation |
| Q35900978 | Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis |
| Q57044016 | Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease |
| Q34396189 | Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation |
| Q50066002 | Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. |
| Q35561981 | Stem cell transplantation???harnessing of graft-versus-malignancy |
| Q86833832 | Steroid-refractory acute graft-versus-host disease: is there an effective therapy? |
| Q33762874 | Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). |
| Q78757439 | Symptoms of pain and depression in related marrow donors: changes after transplant |
| Q40347834 | Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome |
| Q61050855 | T-cell depletion in GVHD: less is more? |
| Q36055158 | Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia |
| Q34077792 | Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. |
| Q91397924 | Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial |
| Q36851405 | Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. |
| Q91480668 | Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease |
| Q35784522 | Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease |
| Q42100800 | The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation |
| Q36734547 | The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial |
| Q36368111 | The clinical spectrum of acute graft-versus-host disease |
| Q36463393 | The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy |
| Q37143670 | The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation |
| Q35633215 | The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation |
| Q34607576 | The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation |
| Q34033852 | The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission |
| Q37738452 | The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. |
| Q37376862 | The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review |
| Q92234069 | The role of regulatory T cells in graft-versus-host disease management |
| Q40168999 | The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT. |
| Q91582282 | Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape |
| Q41563521 | Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner |
| Q92056599 | Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease |
| Q36547819 | Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. |
| Q34156279 | Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation |
| Q58793795 | Upper gastrointestinal acute graft--host disease adds minimal prognostic value in isolation or with other graft--host disease symptoms as currently diagnosed and treated |
| Q34827332 | Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation |
| Q89777567 | Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT |
| Q33718837 | Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation |
| Q38877336 | Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation |
| Q36458848 | Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation |
| Q33650918 | White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome |
| Q61446069 | Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation |
| Q46496613 | Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. |
| Q50044411 | α1-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease |
Search more.